`
`UNITED STATES DISTRICT COURT
`SOUTHERN DISTRICT OF NEW YORK
`-------------------------------------------------------)(
`
`MEDISIM LTD.,
`
`Plaintiff,
`
`- against-
`
`BESTMED LLC,
`
`Defendant.
`
`OPINION AND
`
`ORDER
`
`
`10 Civ. 2463 (SAS)
`
`
`-------------------------------------------------------)(
`SHIRA A. SCHEINDLIN, U.S.D.J.:
`
`I.
`
`INTRODUCTION
`
`This is an action for the infringement of a patent for a non-invasive
`
`thermometer. The case was tried to a jury, which returned a verdict finding that
`
`defendant BestMed LLC ("BestMed") willfully infringed on U.S. Patent No.
`
`7,597,668 ("the '668 Patent"), of which plaintiff Medisim Ltd. ("Medisim") is the
`
`sole assignee and owner. The jury also found that BestMed infringed Medisim's
`
`copyright in the Instructions for Use ("IFU") for its thermometers, and that
`
`BestMed was unjustly enriched under New York law. The jury awarded Medisirn
`
`$1.2 million for its patent infringement claim, and $2.29 million for its unjust
`
`enrichment claim. Medisim sought only equitable relief for its copyright claim.
`
`-1
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 2 of 69
`
`Presently before the Court is BestMed’s post-trial motion for
`
`judgment as a matter of law (“JMOL”), or, alternatively, for a new trial. BestMed
`
`asserts the following grounds in support of its motion: (1) the ‘668 Patent is invalid
`
`(on four theories); (2) BestMed did not infringe on the ‘668 Patent, directly or
`
`indirectly; (3) there was insufficient evidence of willful infringement; (4) BestMed
`
`is not liable for unjust enrichment under New York law; and (5) Medisim is not
`
`entitled to damages. Also pending are three motions brought by Medisim, seeking,
`
`respectively, a permanent injunction and disposition of infringing materials, post-
`
`trial relief, and a judicial finding of willful infringement.
`
`Although this case was expansive when opening arguments began, it
`
`narrowed substantially prior to the jury’s deliberations. Specifically, the evidence
`
`presented at trial narrowed the anticipation inquiry to the question of whether the
`
`prior art FHT-1 thermometer meets the ‘deep tissue temperature’ limitation of the
`
`‘668 Patent. The jury’s verdict of no anticipation implicitly answered this question
`
`in the negative. However, the evidence presented at trial clearly and convincingly
`
`demonstrates that the FHT-1 calculates ‘deep tissue temperature,’ and no
`
`reasonable jury could have found otherwise. Therefore, BestMed’s motion for
`
`JMOL on anticipation is granted.
`
`Similarly, Medisim’s claim for unjust enrichment was narrowed
`
`-2-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 3 of 69
`
`substantially prior to its submission to the jury. Because substantial evidence does
`
`not support the jury’s verdict awarding damages to Medisim for unjust enrichment,
`
`JMOL on unjust enrichment is granted. Finally, Medisim’s pending motions are
`
`denied, save for its motion for an injunction disposing of materials infringing its
`
`copyright, which is granted.
`
`II.
`
`BACKGROUND1
`
`BestMed’s motion for a JMOL of invalidity and non-infringement
`
`turns entirely on an exceedingly narrow issue: whether the FHT-1 thermometer, a
`
`non-invasive temple thermometer sold by Medisim more than one year prior to the
`
`effective date of the ‘668 Patent, meets the deep tissue temperature limitation of
`
`2
`the ‘668 Patent. When placed in its proper context, it is plain that this issue must
`
`be resolved in BestMed’s favor.
`
`Providing the proper context is a difficult undertaking in light of this
`
`1
`The facts of this case have been recited in numerous opinions over the
`course of this litigation. See, e.g., Medisim Ltd. v. BestMed LLC (the “S.J. Op.”),
`No. 10 Civ. 2463, – F. Supp. 2d –, 2012 WL 5954757, at *1 (S.D.N.Y. Nov. 28,
`2012) (ruling on the parties’ cross motions for summary judgment). Familiarity
`with these prior opinions is assumed.
`
`2
`“FHT” means “forehead thermometer,” and the designation refers to
`Medisim’s line of non-invasive (or semi-invasive, e.g., armpit) thermometers. See
`Trial Transcript (“Tr.”) (Direct Examination of Moshe Yarden (“Yarden Direct”))
`at 106:9. Medisim also had a line of invasive thermometers, which are designated
`M5T. See id. (Cross-Examination of Stanley Cohen (“Cohen Cross”)) at 745:14-
`19.
`
`-3-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 4 of 69
`
`case’s technical complexity, thorny procedural history, and voluminous trial
`
`record. Moreover, when considering a post-trial motion for JMOL, a court must
`
`take the utmost care not to impinge upon the vital role of the jury in our judicial
`
`system. For these reasons, although the material question in this case is narrow
`
`and readily resolved, it is necessary to provide a detailed recitation of the facts
`
`relevant to validity and infringement.
`
`The section below therefore recites a full account of the facts,
`
`beginning with the Court’s claim construction, and ending with the evidence
`
`adduced at trial. It then summarizes the facts relevant to BestMed’s motion to set
`
`aside the verdict of unjust enrichment.
`
`A.
`
`Claim Construction
`
`The ‘668 Patent was filed on May 31, 2006 and issued on October 6,
`
`3
`2009 to Moshe Yarden, one of Medisim’s founding partners. It incorporates by
`
`reference an earlier patent, U.S. Patent No. 6,280,397 (“the ‘397 Patent”), which
`
`was issued on August 28, 2001. The ‘397 Patent names Yarden as a co-inventor,
`
`and is also assigned to Medisim.4
`
`See Stipulation of Undisputed Facts (“Stip. Facts”), Ex. A to Joint
`3
`Pre-Trial Order, ¶¶ 2; 8.
`
`See Medisim Ltd. v. BestMed LLC (the “Markman Op.”), No. 10 Civ.
`4
`2463, 2011 WL 2693896, at *1 (S.D.N.Y. July 8, 2011).
`
`-4-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 5 of 69
`
`The ‘668 Patent is titled “Non-Invasive Temperature Measurement.”
`
`As this title suggests, the claimed invention relates to a non-invasive thermometer.
`
`The ‘668 Patent contains two independent claims: an apparatus claim and a method
`
`claim. Claim 1, the independent apparatus claim, states:
`
`
`
`
`
`A thermometric device, comprising:
`
`a probe, comprising:
`
`a membrane configured to be applied to an external
`surface of a body of a subject; and
`
`one or more temperature sensors located within the
`probe in thermal contact with the membrane; and
`
`a processing unit configured to receive a plurality of
`temperature readings from
`the one or more
`temperature sensors, to determine time-dependent
`parameters of temperature change responsively to the
`plurality of temperature readings to calculate, a deep
`tissue temperature of the body at a location under
`the skin that is a source of heat conducted to the one
`or more temperature sensors, and to calculate a core
`body temperature by correcting for a difference
`between the core body temperature and the deep
`tissue temperature.5
`
`In my Markman Order, I gave the following constructions to the disputed terms in
`
`Claim 1:
`
`
`“Probe” means “portion of thermometer including a membrane
`
`5
`‘668 Patent at col. 10:1-18 (emphasis added to demarcate the “deep
`tissue temperature” limitation).
`
`-5-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 6 of 69
`
`and one or more temperature sensors that touches the exterior
`skin.”
`
`“Membrane” means “a layer or sheet of material.”
`
`“One or more temperature sensors” means “one or more
`thermistor or resistance temperature defectors (RTDs), or any
`form of thermistor, temperature sensor, or thermocouple.”
`
`“Configured to receive a plurality of temperature readings from
`the one or more temperature sensors” means “configured to
`receive temperature readings, at least one of which comes from
`the external body surface, from one or more temperature sensors.”
`
`“Time-dependent parameters of temperature change,” means
`“multiple values of temperature change that vary with time and
`that are taken at different times.”
`
`“To calculate” [means] “using a computation to estimate,
`approximate, predict or determine.”
`
`“Core body temperature” [means] “the temperature of blood in the
`pulmonary artery.”6
`
`The independent method claim of the ‘668 Patent, Claim 21, states:
`
`A method for thermometric measurement, comprising:
`
`applying a probe, which comprises a heat-conducting
`membrane and one or more temperature sensors in thermal
`communication with the membrane, to an external surface
`of a body of a subject;
`
`receiving a plurality of temperature readings from the one
`or more temperature sensors while the probe is applied to
`
`
`
`6
`10:1-18).
`
`Markman Op., 2011 WL 2693896, at *11 (quoting ‘668 Patent at col.
`
`-6-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 7 of 69
`
`the surface of the body;
`
`determining time-dependent parameters of temperature
`change responsively to the plurality of temperature
`readings;
`
`calculating a deep tissue temperature of the body at a
`location under the skin that is a source of heat conducted to
`the one or more temperature sensors; and calculating a core
`body temperature by correcting for a difference between the
`core body temperature and the deep tissue temperature.7
`
`My Markman order construed Claim 21 as follows: “the user is ‘applying a probe .
`
`. . to an external surface,’ while the processing unit is ‘receiving a plurality of
`
`temperature readings’; ‘determining time-dependent parameters of temperature
`
`change’; ‘calculating a deep tissue temperature’ and ‘calculating a core body
`
`temperature.’”8
`
`B.
`
`The Deep Tissue Temperature Limitation
`
`The only dispute as to anticipation is whether the FHT-1 meets the
`
`9
`deep tissue limitation of the ‘668 Patent. This section sets forth the facts of record
`
`7
`
`‘668 Patent at col. 11:25-41.
`
`8
`11:25-41).
`
`Markman Op., 2011 WL 2693896, at *11 (quoting ‘668 Patent at col.
`
`See BestMed’s Memorandum in Support of Its Motion for JMOL or,
`9
`Alternatively, for a New Trial (“Def. Mem.”) at 2; Memorandum in Support of
`Medisim’s Opposition to BestMed’s Motion for JMOL, or, Alternatively for a New
`Trial (“Opp. Mem.”) at 3-4.
`
`-7-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 8 of 69
`
`relevant to this limitation, including: (1) the intrinsic evidence; (2) the procedural
`
`history; and (3) the evidence presented at trial.
`
`1.
`
`Intrinsic Evidence
`
`a.
`
`Claim Construction
`
`i.
`
`“Deep Tissue Temperature”
`
`Medisim advanced the following construction of “deep tissue
`
`temperature” in its Markman brief: “stable temperature under the skin that is
`
`minimally affected by external factors and is the source of heat conducted to the
`
`10
`one or more sensors.” BestMed advanced the construction that “deep tissue
`
`temperature” means “a heat source below the skin.” At the Markman hearing,
`11
`
`though, the parties agreed that the term did not need to be construed,
`
`12
`
` and I
`
`subsequently declined to construe it.
`
` 13
`
`The litigation therefore proceeded on the assumption that “deep tissue
`
`temperature” was to be given its plain and ordinary meaning in the context of the
`
`10
`
`3/4/11 Plaintiff’s Opening Claim Construction Brief, Doc. No. 33, at
`
`15.
`
`11
`3/4/11 Opening Claim Construction Brief by BestMed (“Def.
`Markman Br.”), Doc. No. 34, at 18.
`
`12
`
`13
`
`See 4/28/11 Hearing Transcript at 108:18-19.
`
`See Markman Op., 2011 WL 2693896, at *9.
`
`-8-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 9 of 69
`
`14
`intrinsic evidence.
`
` There is no dispute that, in the ‘668 Patent, the term “deep
`
`tissue temperature” “reflects” the “temperature at a location under the skin that is
`
`the source of heat conducted to the sensors in the probe. . . .”15
`
`Two points follow directly from this construction of “deep tissue
`
`temperature.” First, plainly, the “source of heat” that causes the measured
`
`“temperature at a location under the skin” will vary depending upon where the
`
`probe is applied. For example, if the probe were applied to the temple, the source
`
`of heat would be the temporal artery, and the deep tissue temperature would
`
`therefore approximate this temperature. Second, “deep tissue temperature” (also
`
`called “local temperature” in the ‘668 Patent) is distinct from “surface
`
`temperature,” i.e., the temperature of the exterior skin, and from “core
`
`temperature,” i.e. the temperature of the pulmonary artery.
`
`ii.
`
`The Deep Tissue Temperature Limitation
`
`During Markman proceedings, BestMed contended that the deep
`
`tissue temperature limitation — as opposed to the phrase “deep tissue temperature”
`
`See Biogen Idec, Inc. v. GlaxoSmithKline LLC, No. 2012-1120, – F.3d
`14
`–, 2013 WL 1603360, at *4 (Fed. Cir. Apr. 16, 2013) (“[A] term’s ordinary
`meaning must be considered in the context of all the intrinsic evidence, including
`the claims, specification, and prosecution history.”) (citations omitted).
`
`‘668 Patent at col. 2:3-5. See Tr. (Medisim Summation) at 1617:20-
`15
`22 (“And the parties agreed that local or deep tissue temperature is the temperature,
`the heat under the skin, that’s not in dispute.”).
`
`-9-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 10 of 69
`
`in isolation — is a means-plus-function claim under Title 35 of the United States
`
`Code, Section 112, ¶ 6. Specifically, BestMed argued that although the limitation
`
`does not use the catch-word “means,” it nevertheless employs means-plus-function
`
`claiming, because the only structure that the ‘668 Patent discloses is a generic
`
`“processing unit,” and the only method it discloses for calculating a deep tissue
`
`16
`temperature is the ‘397 algorithm.
`
` Based on this argument, BestMed offered the
`
`following construction of the limitation: “[t]he microprocessor calculates the
`
`temperature of a heat source below the skin’s surface according to the algorithm
`
`set forth in [the ‘397 Patent at col. 1:1-58-col. 2:1-57 (the “‘397 algorithm”)].” 17
`
`Because of the presumption against means-plus-function claiming
`
`created by the absence of the word “means,” and because the specification of the
`
`‘668 Patent disclosed sufficient structure, I did not construe the deep tissue
`
`18
`temperature limitation as a means-plus-function claim.
`
` This ruling resolved sub
`
`silentio BestMed’s argument that the ‘668 Patent did not disclose sufficient
`
`16
`
`17
`
`See id. at 19-21.
`
`Def. Markman Br. at 19.
`
`See Markman Op., 2011 WL 2693896, at *10 (“In light of the strong
`18
`presumption against applying § 112, ¶ 6 and this claim language, I find that
`‘processing unit’ connotes a sufficiently definite structure to a person of ordinary
`skill in the art to avoid § 112, ¶ 6 treatment.”) (citing Inventio AG v. ThyssenKrupp
`Elevator Americas Corp., 649 F.3d 1350, 1360 (Fed. Cir. 2011)).
`
`-10-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 11 of 69
`
`structure to calculate a deep tissue temperature by any means other than through
`
`19
`the ‘397 algorithm,
`
` an argument properly addressed to enablement, not the
`
`analysis of means-plus-function claiming.
`
`b.
`
`Deriving Deep Tissue Temperature
`
`Although the parties agree on the construction of the term deep tissue
`
`temperature, they dispute how that temperature is derived. The intrinsic evidence
`
`sheds some light on this dispute. The ‘668 Patent indicates that deep tissue
`
`temperature may be derived from the heat-flux algorithm of the ‘397 Patent, and
`
`discloses an embodiment in which a two-sensor probe applied to an external body
`
`surface uses the output of the ‘397 Patent in conjunction with an empirically
`
`derived formula to determine the user’s core body temperature. Moreover, the
`
`prosecution history of the ‘668 Patent estops Medisim from denying that a user’s
`
`deep tissue temperature may be derived from an infrared thermometer applied to
`
`the user’s forehead.
`
`i.
`
`The ‘668 Patent
`
`The ‘668 Patent states that “[t]he thermometer is configured to
`
`perform the heat flux calculation [e.g., an algorithm similar, or identical, to that
`
`Def. Markman Br. at 20 (“The ‘668 Patent teaches no algorithm for
`19
`calculating deep tissue temperature, except vis-a-vis the ‘397 Patent . . . . Thus, the
`subject claim phrase is subject to §112, ¶ 6, and should be construed as limited to
`the ‘397 Patent algorithm.”).
`
`-11-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 12 of 69
`
`disclosed in the ‘397 Patent] so as to derive a value of the [] [deep tissue]
`
`20
`temperature.” In particular, the ‘668 Patent discloses an embodiment in which,
`
`[u]sing the heat flux algorithm described in the . . . [‘397 Patent],
`the processing unit calculates from the temperature readings a
`local temperature. The local temperature, also referred to as a
`deep tissue temperature, reflects a temperature at a location under
`the skin that is the source of heat conducted to the sensors in the
`probe.21
`
`The ‘668 Patent teaches that a reliable approximation of core temperature may be
`
`derived from a measurement of the skin’s surface temperature if this temperature is
`
`first converted to an approximation of deep tissue temperature. It states that:
`
`The local temperature determined by the ‘397 algorithm is less
`affected than the surface temperature at the measurement site is
`[by] external factors such as ambient temperature and humidity.
`The local temperature is also less subject to variations in the
`body’s heat regulation at the body’s extremities. Consequently,
`there is a closer correlation between local temperature and core
`body temperature than there is between surface temperature and
`core body temperature.22
`
`The Appendix of the ‘668 Patent (the “Appendix”) teaches that the
`
`‘397 Patent “provides a method for rapidly determining a core body temperature
`
`based on heat flux through a thermometer when the thermometer is inserted into an
`
`20
`
`21
`
`22
`
`‘668 Patent at col. 2:6-7.
`
`Id. at col. 6:55-62.
`
`Id. at col. 7:1-8.
`
`-12-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 13 of 69
`
`23
`orifice of the body.” The ‘668 Patent further states that “[t]he accuracy of the
`
`derived temperature of [the ‘397 patent] is diminished when temperature
`
`measurements are made at an external measurement site on the body[,]” and goes
`
`on to provide an embodiment of the claimed invention in which “an empirically
`
`derived formula is used by the processing unit to determine core body temperature
`
`based on temperature readings made by sensors within the probe when the probe is
`
`applied to an external body surface.”24
`
`It is necessary to summarize this formula in order to properly evaluate
`
`BestMed’s anticipation contentions. The inputs to the formula are “temperature
`
`readings from two sensors: a first sensor positioned at a shorter thermal distance
`
`25
`from the thermometer membrane, and a second sensor at a farther distance.” In
`
`the exemplary embodiment disclosed by the Appendix, these temperature readings
`
`are taken ten times at 0.4 seconds intervals.26
`
`The formula comprises nine constants, each used only once, and six
`
`variables. It is the sum of nine terms: (1) one constant; (2-6) five variables, each of
`
`23
`
`24
`
`25
`
`26
`
`Id. at col. 9:15-18.
`
`Id. at col. 9:15-27.
`
`Id. at col. 9:27-29.
`
`See id. at col. 9:47-52.
`
`-13-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 14 of 69
`
`which is multiplied by a separate constant; and (7-9) one variable used three times,
`
`in third-order polynomial form, and multiplied by a separate constant in each of its
`
`three appearances.27
`
`The nine constants are empirically derived. Five of the six variables
`
`used are: (1) the difference between the second and final temperature readings of
`
`the first sensor, i.e., the sensor that is closer to the “layer or sheet of material”
`
`28
`covering the probe and in thermal contact with the skin;
`
` (2-3) the rate of change,
`
`in degrees per second, of the first and second sensors after five intervals; and (4-5)
`
`the readings of the first and second sensors after the final interval.29
`
`The sixth variable used in the formula is “T [,]” which is defined by
`avg
`
`30
`the ‘668 Patent as “the heat-flux derived temperature of [the ‘397 Patent].” The
`
`‘397 Patent claims “[a] high speed accurate temperature measuring device
`
`See id. at col. 9:34-36 (providing the equation “Core Body
`27
`Temperature = (C x T
`) + (C
` x T
`) + (C
` x T
`) + (C x T ) + (C x
`5
`b10-2
`rdot5
`rdot5
`bdot5
`bdot5
`r10
`r10
`b10
`2
`3
`T ) + (C x T ) + (C x (T )) + (C x (T )) + C )”).
`b10
`3
`avg
`avg
`7
`avg
`6
`4
`
`Markman Op., 2011 WL 2693896, at *11 (construing the term
`28
`“membrane”).
`
`29
`
`See ‘668 Patent at col. 9:52-61.
`
`Id. at col. 9:62-63. The ‘397 Patent was introduced into evidence as
`30
`Exhibit 48. See Tr. (Yarden Direct) at 100:24-101:1 (identifying exhibit as the
`‘397 Patent).
`
`-14-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 15 of 69
`
`31
`especially useful[] for measuring human body temperature[,]” and teaches an
`
`algorithm “whereby the body temperature is calculated according to heat flux [i.e.,
`
`the rate of heat energy transfer] measured (a) between the body and a first
`
`temperature sensor and (b) between the first temperature sensor and a second
`
`32
`temperature sensor (or sensors).” In essence, the ‘397 algorithm is a method of
`
`rapidly predicting the thermoequilibrium temperature of the human body by taking
`
`temperature measurements at known intervals with two or more parallel sensors,
`
`separated by a known distance, with an insulating material of known thermal
`
`conductivity interposed between them, and with one sensor in thermal contact with
`
`the body (either directly or by being in thermal contact with a membrane that is in
`
`thermal contact with the body).33
`
`The specification of the ‘668 Patent refers to variables (1-3) of the
`
`formula disclosed in the Appendix as “time dependent parameters of temperature
`
`change,” and, unsurprisingly, refers to variables (4-5) as merely “temperature
`
`31
`‘397 Patent at col. 5:46-47. The ‘397 Patent does not mention core
`body temperature or deep tissue temperature, and appears to have been intended
`for invasive use. See id. at col. 6:1-2 (Claim 1) (claiming “an elongated
`temperature probe with a rounded insertion tip for insertion into a body cavity”).
`
`Id. at col. 1:46-49. See Tr. (Yarden Direct) at 84:3-6 (“[H]eat is [the]
`32
`amount of energy. Heat flux [is the] amount of energy that [is] passing across a
`given area for a given period of time.”) (emphasis added).
`
`33
`
`See ‘397 Patent at col. 1:27-43; id. at col. 2:38-57.
`
`-15-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 16 of 69
`
`measurements. . . .” The sixth variable, i.e., the output of the ‘397 algorithm, or
`34
`
`avgT , is identified by the ‘668 Patent as local body temperature.
`
` 35
`
`The ‘668 Patent further states that T is calculated “using a function
`avg
`
`36
`including the time-dependent parameters [of temperature change][;]” another
`
`unsurprising statement, given that the inputs to the ‘397 algorithm (time-dependent
`
`temperature measurements taken by two sensors) correspond to the time-dependent
`
`parameters of temperature change used in the empirical formula disclosed in the
`
`37
`Appendix.
`
` (In my Markman order, I held that “‘time-dependent parameters of
`
`temperature change’ encompasses straight temperature difference [e.g. the reading
`
`of sensor one at interval ten minus the reading of sensor one at interval two] as
`
`34
`‘668 Patent at col. 2:8-12 (“The thermometer is configured to perform
`the heat flux calculation so as to derive a value of the local temperature. The local
`temperature, together with the temperature measurements and the time dependent
`parameters of temperature change may then be used to calculate a core body
`temperature. The calculation is typically based on an empirically derived formula
`based on the aforementioned parameters.”)
`
`See id. See also id. at col. 7:12-17 (“The formula [disclosed in the
`35
`Appendix] is based on fitting a linear equation comprising several
`temperature-related parameters to clinically measured values of core body
`temperature. The temperature related parameters include sensor temperature
`readings, time-dependent temperature rates of change, and the value of local body
`temperature determined by the ‘397 algorithm.”).
`
`36
`
`37
`
`Id. at col. 2:42-44.
`
`See ‘397 Patent at col. 4:64-67.
`
`-16-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 17 of 69
`
`well as rates of temperature change.”)38
`
`ii.
`
`Prosecution History
`
`During the prosecution history of the ‘668 Patent, the Examiner issued
`
`a final rejection holding Claims 1-13, 15, 19, 22-28, 33, and 36-38 as obvious over
`
`two references, “Fraden,” which discloses calculating a deep tissue temperature at
`
`the forehead, and “Takashi,” which discloses that the deep tissue temperature
`
`39
`underestimates core temperature.
`
` Yarden overcame this prior art by claiming that
`
`Fraden calculated deep tissue temperature, but taught away from correcting to core
`
`temperature by assuming that deep tissue temperature was a reliable approximation
`
`40
`of core temperature.
`
` Thus, the prosecution history record estops Medisim from
`
`denying that deep tissue temperature may be calculated by applying an infrared
`
`38
`
`Markman Op., 2011 WL 2693896, at *8.
`
`See ‘668 File History, 4/2/09 Final Rejection ¶ 2. Fraden, US Patent
`39
`Application Publication 2005/0043631, discloses a thermometer that utilizes
`infrared technology. According to Yarden, Fraden “calculates deep tissue body
`temperature from time dependent parameters, but does disclose the additional step
`of correcting the deep body temperature to a core body temperature.” Id. Takashi,
`an article from the Japanese Journal of Anaesthesiology, discloses a study showing
`that non-invasive forehead deep tissue thermometry, such as Fraden,
`underestimates the actual value of the core body temperature. See id.
`
`See ‘668 File History, 9/6/09 Response to Office Action at 10
`40
`(“Applicant respectfully disagrees and respectfully submits that it would not have
`been obvious to one of ordinary skill in the art at the time of the invention to
`modify Fraden’s temperature probe to adjust or correct the deep tissue temperature
`calculated by the probe.”).
`
`-17-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 18 of 69
`
`thermometer to a patient’s forehead.41
`
`The Examiner also considered U.S. Application No. 60/572,651 (the
`
`“‘651 Provisional”), a provisional patent application filed by Yarden prior to his
`
`application for the ‘668 Patent. The ‘651 Provisional is entitled “System for fast,
`
`42
`non-invasive and accurate measurement of an object’s temperature.” A fuller
`
`account of it is provided below.
`
`2.
`
`Procedural History
`
`After my Markman ruling, the parties made cross-motions under
`
`Daubert v. Merrell Dow Pharmaceuticals, Inc.,
`43
`
` as well as Rules 702 and 403 of
`
`the Federal Rules of Evidence, to exclude the testimony of various experts. I ruled
`
`on these motions in an Opinion and Order dated March 6, 2012 (the “Daubert
`
`See Krippelz v. Ford Motor Co., 667 F.3d 1261, 1266 (Fed. Cir. 2012)
`41
`(“A patentee’s statements during reexamination can be considered during claim
`construction, in keeping with the doctrine of prosecution disclaimer.”). The jury
`heard testimony supporting the same proposition. See Tr. (Direct Examination of
`David Lipson (“Lipson Direct”) at 776:16-23 (discussing infrared technology) (“Q.
`If you take such a measurement at the temple, what temperature will you be
`calculating directly? A. If you are reading at this area which is right above, say, the
`temporal artery, you are reading what is now commonly referred to as the local
`deep tissue. It is the temperature under the skin in the tissue between, essentially,
`the artery and underneath the skin.”).
`
`See ‘668 Patent at 2 (listing the ‘651 Provisional among the references
`42
`considered by the Examiner).
`
`43
`
`509 U.S. 579 (1993).
`
`-18-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 19 of 69
`
`Opinion” or “Daubert Op.”), and on the motion for reconsideration subsequently
`
`brought by Medisim in an order dated April 23, 2012 (the “Daubert
`
`Reconsideration Op.”). The parties then brought cross-motions for summary
`
`judgment. I decided these motions in an Opinion and Order dated November 28,
`
`2012 (the “Summary Judgment Opinion” or “S.J. Op.”). The relevant portions of
`
`these pre-trial rulings are summarized below.
`
`a.
`
`The Daubert Opinion
`
`The Summary Judgment Opinion provides the following summary of
`
`my rulings on the parties’ Daubert motions:
`
`1) Jack Goldberg—BestMed’s expert on the validity of the ‘668
`Patent—is qualified to opine in the area of digital, conductive
`thermometry. Goldberg may offer the following opinions: (1) that
`the specification of the ‘668 Patent does not enable the full scope
`of the claimed invention; (2) that Medisim’s FHT-1 Digital
`Temple Thermometer . . . calculates core body temperature and
`therefore anticipated the ‘668 Patent; (3) that the FHT-1 calculates
`deep tissue temperature; and (4) that BestMed has not infringed
`Medisim’s intellectual property. . . .
`
`2) Dr. David Lipson—Medisim’s expert on the validity of the
`‘668 Patent—may opine that BestMed’s KD-2201 thermometer
`meets the core body temperature limitation of the ‘668 Patent.
`Lipson may also testify that the KD-2201 thermometer meets the
`deep tissue temperature limitation of the ‘668 Patent, but only to
`the extent that he bases his opinion on the 510(k) letters and
`deposition testimony of K-Jump witnesses referenced in his
`
`-19-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 20 of 69
`
`
`
`report.44
`
`Lipson sought to testify that the accused device, BestMed’s KD-2201
`
`thermometer, met the deep tissue temperature limitation of the ‘668 Patent. In
`
`support of this conclusion, Lipson offered: (1) his own testing, which supposedly
`
`indicated that the KD-2201, a single-sensor conduction thermometer, measures
`
`deep tissue temperature when placed in ‘test mode’ (i.e., a factory calibration mode
`
`where the actual temperature reading of the sensor is obtained, as opposed to a
`
`derived temperature), applied to the external skin, and allowed to reach
`
`thermoequilibrium; (2) the submissions that K-Jump, the manufacturer of the
`
`accused device, made to the FDA (the “510(k) Letters”) describing the accused
`
`device; and (3) evidence drawn from the deposition of employees at K-Jump who
`
`were involved with designing the accused device (the “K-Jump Depositions”).
`
`45
`
`
`
`In the Daubert opinion, I found that the competent evidence of record
`
`showed that calculating a deep tissue temperature by measuring the
`
`thermoequilibrium temperature at the skin’s surface was possible only through the
`
`zero-heat flux method, which requires at least two sensors and a heating element. I
`
`S.J. Op., 2012 WL 5954757, at *3 (citing Daubert Reconsideration
`44
`Op., No. 10 Civ. 2463, 2012 WL 1450420, at *2 (S.D.N.Y. Apr. 23, 2012);
`Daubert Op., 861 F. Supp. 2d 158, 167-74 (S.D.N.Y. 2012)).
`
`45
`
`See Daubert Reconsideration Op., 2012 WL 1450420, at *2.
`
`-20-
`
`
`
`Case 1:10-cv-02463-SAS Document 210 Filed 05/15/13 Page 21 of 69
`
`also found that utilizing the zero-heat flux method is an impossibility with the
`
`accused device, which lacks a heating element and has only one sensor.
`
`46
`
` On the
`
`basis of this finding, I entirely excluded, as an ipse dixit, Lipson’s conclusion that
`
`the accused product meets the deep tissue temperature limitation of the ‘668
`
`Patent.47
`
`On reconsideration, despite having grave doubts about Lipson’s
`
`ultimate conclusion that the accused product meets the deep tissue temperature
`
`48
`limitation,
`
` I amended my Daubert ruling to allow Lipson to testify to this
`
`conclusion, but only on the basis of the K-Jump Depositions and the 510(k)
`
`See Daubert Op., 861 F. Supp. 2d at 175 & 175 n.121 (citing Michiaki
`46
`Yamakage & Akiyoshi Namiki, Deep Temperature Monitoring Using a Zero-Heat-
`Flow Method, 17 J. Anesthesia 108, 111 (2003); Daniel I. Sessler, Temperature
`Monitoring and Perioperative Thermoregulation, 109 Anesthesiology 318, 319
`(2008). Prior to trial, the parties stipulated that “[t]he scientific literature of record
`in this case shows that deep tissue temperature can be calculated from the skin’s
`surface using zero-heat-flux.” Stip. Facts ¶ 9.
`
`See Daubert Op., 861 F. Supp. 2d at 175-76 (“Lipson’s determination
`47
`that the KD-2201 measures deep tissue temperature at the skin surface is an
`unsupported ipse dixit conclusion. . . . Accordingly, Lipson may not testify that the
`KD-2201 meets the deep tissue temperature limitation of the ‘668 Patent.”)
`(citations omitted).
`
`See Daubert Reconsideration Op., 2012 WL 1450420, at *2 (S.D.N.Y.
`48
`2012) (“I have serious doubts regarding whether Lipson’s ‘deep tissue
`temperature’ opini